Jiang Yu | Biological Sciences | Best Researcher Award

Dr. Jiang Yu | Biological Sciences Best Researcher Award

Jiang Yu, Ph.D., is a Full Professor at the Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Sciences. Her research focuses on the molecular immunity of swine diseases and vaccine development, with three vaccine products successfully transferred to enterprises. In 2022, she became Group Leader for Swine Disease Monitoring and Warning. Jiang holds multiple international patents and has published extensively in leading journals, advancing diagnostics and prevention strategies for animal diseases. Her expertise lies in microbiology, immunology, and innovative solutions for swine health management.

Dr. Jiang Yu | Shandong Academy of Agricultural Sciences | China

Profile

SCOPUS ID

🎓 Education

  • Jiang Yu earned her Ph.D. degree in 2014, specializing in the field of molecular immunity and swine disease prevention. Her academic foundation laid the groundwork for her innovative contributions to animal science and veterinary medicine.

💼 Experience

  • Currently a Full Professor at the Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Sciences, Jiang Yu has been a leader in her field, focusing on molecular immunity and vaccine research for major swine diseases. In 2022, she took on the role of Group Leader for Swine Disease Monitoring and Warning, guiding advancements in disease detection and prevention. Her research achievements have led to the successful transfer of three vaccine products to enterprises, highlighting her impact on industry and animal health.

 🏆 Honors and Awards

  • Jiang Yu’s work has been recognized with multiple awards for innovation in veterinary science. Her patented technologies, including ELISA test kits and advanced vaccine preparation methods, demonstrate her commitment to enhancing swine disease management. Her contributions extend internationally, with patents in the United States, South Africa, Luxembourg, and China.

🛠️ Skills and Certifications

  • Jiang Yu possesses a unique blend of research expertise, including molecular biology, microbiology, and immunology. Her skills in vaccine development, disease monitoring, and diagnostic kit design have positioned her as a pioneer in animal disease prevention and control.

🔬 Research Focus

  • Jiang Yu’s primary research revolves around the prevention and control of animal diseases, particularly swine infectious diseases. Her work explores microbiology, immunity, and the development of innovative vaccines and diagnostic tools. Her contributions, such as elucidating the role of pattern recognition receptors in PRRSV infection and developing novel therapeutic platforms for influenza and bacterial infections, have significantly advanced the field.

Conclusion

  • Jiang Yu’s contributions to veterinary science and animal health are highly significant. Her ability to combine fundamental research with practical applications positions her as a key figure in combating major swine diseases. By enhancing her international presence and focusing on outreach, she can further solidify her status as a global leader in her field. Her achievements make her a strong contender for the Best Researcher Award.

📄Publications

  • m6A-modified exosome-derived circHIF1α binding to KH domain of IGF2BP3 mediates DNA damage and arrests G1/S transition phase to resist bacterial infection in bacteremia
    Authors: Yu, J., Gao, Y., Liu, F., Sun, W., Wu, J.
    Journal: Journal of Nanobiotechnology, 2024, 22(1), 654
  • Important role of Bacillus subtilis as a probiotic and vaccine carrier in animal health maintenance
    Authors: Yuan, C., Ji, X., Zhang, Y., Yu, J., Wu, J.
    Journal: World Journal of Microbiology and Biotechnology, 2024, 40(9), 268
  • Research progress on the pattern recognition receptors involved in porcine reproductive and respiratory syndrome virus infection
    Authors: Xu, Y., Ding, L., Zhang, Y., Yu, J., Wu, J.
    Journal: Frontiers in Cellular and Infection Microbiology, 2024, 14, 1428447
  • Covalent Organic Framework-Based Theranostic Platforms for Restricting H1N1 Influenza Virus Infection
    Authors: Ding, L.-G., Ji, X., Liu, Y.-Y., Yu, J., Wu, J.-Q.
    Journal: International Journal of Nanomedicine, 2024, 19, pp. 7399–7414
  • Mechanisms and applications of probiotics in prevention and treatment of swine diseases
    Authors: Zhang, Y., Zhang, Y., Liu, F., Wu, J., Yu, J.
    Journal: Porcine Health Management, 2023, 9(1), 5

Zongzhi Liu | Bioinformatics | Best Researcher Award

Assoc Prof Dr.Zongzhi Liu | Bioinformatics | Best Researcher Award

Successful Research Projects:
  • Dr. Liu has led significant projects, including the study of RUNX3 methylation’s impact on T cell function and immunotherapy response. His successful acquisition of funding for multiple National Natural Science Foundation projects reflects his ability to secure resources for impactful research.
Assoc Prof Dr. Zongzhi Liu , Changping Laboratory, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Zongzhi Liu’s academic journey is deeply rooted in the exploration of human diseases and immunotherapy. His early academic work laid the foundation for his current focus on the mechanisms of neurodegenerative diseases and tumor immunotherapy. By leveraging next-generation sequencing and bioinformatics, he has significantly contributed to the understanding of disease pathways and therapeutic targets.

👨‍🔬  Professional Endeavors

  • Liu’s professional endeavors are characterized by his commitment to precision medicine and epigenetic research. His notable projects include the development of epigenetic biomarkers for early cancer diagnosis and targeted therapy. His work with Runx3 knockout mouse models has provided critical insights into the epigenetic regulation of PD-1 tumor treatment response and resistance.

🔬 SCADEN Algorithm and Neurodegenerative Diseases

  • Liu utilized the SCADEN algorithm to predict primary pathways involved in neuron degeneration, specifically focusing on Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). His research integrates behavioral experiments in mice to explore these mechanisms further.

🧫 Multi-Omics Analysis for Tumor Immunotherapy

  • Through multi-omics analysis, Liu identified epigenetic targets for tumor immunotherapy. His establishment of a Runx3 knockout mouse model was pivotal in demonstrating that Runx3 epigenetic reprogramming is a key regulator of PD-1 tumor treatment response and resistance.

🌐 Research and Innovations

  • Liu’s innovations extend to several high-impact projects:

    • Molecular Mechanism of T Cell Function: Studied the regulation of T cell function related to RUNX3 methylation reprogramming, funded by the National Natural Science Foundation (2023-2025).
    • Emerging Infectious Diseases: Contributed to pathogen identification and early warning technology for infectious diseases, as part of a national task (2021-2024).
    • Combined Immunotherapy: Investigated the synergistic effects of combined immunotherapy, with significant clinical implications (2016-2022).
    • Maternal Age and Pregnancy Outcomes: Explored the impact of advanced maternal age on pregnancy outcomes and offspring health (2018-2022).
    • Liquid Biopsy Technology: Evaluated liquid biopsy technology for early cancer screening and diagnosis (2019-2021).

🏢 Consultancy/Industry Projects

  • National Natural Science Foundation Project: Molecular mechanism study on T cell function regulation (2023-2025).
  • National Task Project: Study on pathogen identification and early warning technology (2021-2024).
  • National Key R&D Program: Research on combined immunotherapy (2016-2022).
  • National Natural Science Foundation Key Project: Impact of advanced maternal age on pregnancy outcomes (2018-2022).
  • Ministry of Science and Technology Key R&D Program: Liquid biopsy technology for early cancer diagnosis (2019-2021).

🌍 Impact and Influence

  • Liu’s research has significantly impacted the fields of neurodegenerative diseases and tumor immunotherapy. His work on epigenetic reprogramming and precision medicine has paved the way for innovative approaches to early diagnosis and targeted therapy, influencing both clinical practices and future research directions.

👩‍🔬 Professional Memberships AND Collaborations

  • Zongzhi Liu holds esteemed editorial appointments as a reviewer for Frontiers in Oncology and Frontiers in Pediatrics, contributing his expertise to the peer-review process. His collaborative efforts span multiple prestigious institutions, including the General Hospital of the People’s Liberation Army of China, the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences, Peking University Third Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences. As a member of the Chinese Society for Cell Biology, Liu actively participates in advancing the field of bioinformatics in human diseases. His research focuses on bioinformatics, with a particular interest in the mechanisms of neurodegenerative diseases and tumor immunotherapy, underscoring his commitment to the intersection of epigenetics and precision medicine.

🌟 Legacy and Future Contributions

  • Liu’s legacy in the scientific community is marked by his groundbreaking research and dedication to advancing medical science. His future contributions are anticipated to further enhance our understanding of disease mechanisms and therapeutic strategies, ultimately improving patient outcomes and shaping the future of precision medicine.

📄Publications

  • Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
    • Authors: Liu, Z., Li, X., Gao, Y., Mei, Q., Sun, Y.
    • Journal: Molecular Cancer, 2023, 22(1), 84
  • CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
    • Authors: Liu, Z., Gao, X., Kan, C., Zhang, Z., Sun, Y.
    • Journal: MedComm, 2023, 4(1), e208
  • Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    • Authors: Jing, C., Wang, J., Zhu, M., Zhang, Z., Deng, W.
    • Journal: Cancer Immunology, Immunotherapy, 2022, 71(11), pp. 2597–2608
  • Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer
    • Authors: Hai, L., Li, L., Liu, Z., Tong, Z., Sun, Y.
    • Journal: MedComm, 2022, 3(3), e134
  • Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
    • Authors: Wang, Y., Tong, C., Dai, H., Zhang, Y., Han, W.
    • Journal: Nature Communications, 2021, 12(1), 409